查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968489

CGRP抑制劑市場－全球產業規模、佔有率、趨勢、機會、預測：治療方法、給藥途徑、最終用戶、地區和競爭格局，2021-2031年

CGRP Inhibitor Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Route of Administration, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 CGRP 抑制劑市場預計將從 2025 年的 36.2 億美元成長到 2031 年的 63.2 億美元，複合年成長率達到 9.73%。

這些抑制劑屬於一類特殊的藥物療法，包括單株抗體和小分子拮抗劑，它們透過抑制抑鈣素基因相關胜肽（CGRP）或其受體來預防偏頭痛的發作。推動這一成長的關鍵因素包括全球慢性頭痛疾病發生率的上升，以及臨床治療策略從急性症狀管理到預防性治療策略的顯著轉變。此外，與傳統曲坦類藥物相比，安全性更高的治療方法越來越受到患者的青睞，這也促進了這些標靶治療的應用。

市場概覽
預測期 2027-2031
市場規模：2025年 36.2億美元
市場規模：2031年 63.2億美元
複合年成長率：2026-2031年 9.73%
成長最快的細分市場 口服
最大的市場 北美洲

另一方面，對偏頭痛症狀的偏見和低估是市場成長的主要障礙，常常導致診斷延誤和患者難以獲得最先進治療。這種認知不足限制了符合處方治療條件的患者族群。歐洲偏頭痛和頭痛協會2024年的報告指出，74%的偏頭痛患者認為他們的病情沒有得到醫療專業人員的重視。因此，這些專業人員認知方面的障礙嚴重阻礙了昂貴的CGRP抑制劑療法的廣泛應用和醫療覆蓋範圍。

市場促進因素

全球偏頭痛和頭痛疾病盛行率的不斷上升是推動市場擴張的主要動力，也因此迫切需要療效優於特異性治療方法的標靶治療。這種疾病帶來的沉重負擔，包括劇烈疼痛和經濟影響，正促使人們轉向特定機制的干涉措施，例如CGRP抑制劑，以滿足尚未充分滿足的醫療需求。環境因素加劇了這一趨勢。正如《國家地理》雜誌2025年12月發表的題為《偏頭痛興起之謎》的文章中所述，美國頭痛協會年會的一項調查顯示，環境溫度每升高10華氏度，頭痛的發生率就會增加6%。這種頻率的增加擴大了潛在患者群體，凸顯了製定強力的預防策略的必要性。世界衛生組織（WHO）2025年10月發布的一份情況說明書進一步證實了這一規模，該說明書指出「頭痛疾病影響著全球約40%的人口」。

此外，藥物遞送系統的創新，特別是口服小分子拮抗劑（如吉泮）的研發，為注射單株抗體提供了非侵入性的替代方案，從而加速了市場成長。口服給藥的便利性提高了患者的依從性，並擴大了以往只能使用療效較差的急性期治療方案的陣發性偏頭痛病例的處方機會。這項技術進步顯著提升了行業收入；例如，艾伯維在其2025年1月發布的2024年全年及第四季度財務業績報告中宣布，其口服CGRP抑製劑產品組合（優布瑞和克瑞普塔）的全球總合銷售額已達到16.64億美元。如此快速的商業性化應用表明，市場明顯偏好更便捷的給藥方式，也證明了製藥業向傳統注射劑以外的給藥途徑進行策略性擴張的合理性。

市場挑戰

對偏頭痛的偏見和輕視是全球CGRP抑制劑市場成長的重大障礙。這種持續存在的負面認知阻礙了患者尋求專業醫療建議，導致他們依賴療效較差的急性治療而非預防措施。當偏頭痛被簡單地視為頭痛時，患者就更不願意諮詢神經科醫生正是高級CGRP抑制劑的主要處方醫生。這種孤立實際上造成了患者就醫管道的瓶頸，使得相當一部分合格的患者無法獲得準確的診斷和先進的藥物。

此外，社會上的懷疑態度對醫療服務的可近性和報銷機制產生了負面影響，從而限制了昂貴治療方法的商業性化應用。根據美國偏頭痛基金會2024年的數據，31.7%的偏頭痛患者經常遭受社會歧視，而這種歧視與更高的殘疾負擔有關。這種普遍存在的認知不足降低了支付方核准昂貴生物製藥保險的迫切性。因此，市場難以將疾病的高發生率轉化為實際的收入成長，而社會上的忽視也限制了這些標靶治療的推廣。

市場趨勢

將急性治療和預防性治療相結合，從根本上改變了傳統的治療模式，改變了市場結構。這一趨勢的特徵是雙效療法的普及，這種療法只需一種藥物即可控制急性發作並預防復發，從而減輕患者的用藥負擔並提高依從性。對於頭痛發作頻率波動的患者而言，這種柔軟性是替代傳統複雜多聯合治療的重要選擇。靈活口服製劑的優異表現證明了這一轉變的商業性成功。正如輝瑞在2024年10月發布的2024年第三季財報中所述，雙適應症CGRP抑制劑Nurtec ODT/Vydura的全球銷售收入年增45%，這證實了臨床上對能夠提供機制特異性控制的簡化治療方法的偏好。

同時，聯合治療作為一種治療單藥治療無效的難治性病例的方法，正日益受到重視。口服小分子藥物注重便利性，但有一部分患者族群需要高效的靜脈製劑，這些製劑通常與其他治療方法（例如A型肉毒桿菌）合併使用，以控制症狀。這種增強策略正在輸注藥物領域創造顯著價值，這與大批量口服藥物市場截然不同。對強效、由醫療專業人員給藥的治療方法的需求得到了強勁銷售的支撐。根據靈北製藥於2024年11月發布的“2024年第一季至第三季中期報告”，其靜脈注射CGRP抑制劑Vyepti的銷售額同比成長76%，表明市場對針對嚴重和難治性患者群體的先進給藥形式的依賴性日益增強。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球CGRP抑制劑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（預防性、急性治療）
    • 給藥途徑（口服、鼻內、靜脈注射）
    • 依最終用戶（醫院、藥局、專科診所）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美CGRP抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲CGRP抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區CGRP抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲CGRP抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲CGRP抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球CGRP抑制劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Eli Lilly and Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • AbbVie Inc.
  • Amgen Inc
  • Novartis AG
  • Allergan
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Sun Pharmaceutical Industries Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19245

The Global CGRP Inhibitor Market is projected to expand from USD 3.62 Billion in 2025 to USD 6.32 Billion by 2031, achieving a CAGR of 9.73%. These inhibitors represent a specialized category of pharmacotherapies, including monoclonal antibodies and small molecule antagonists, which function by blocking calcitonin gene-related peptides or their receptors to avert migraine onset. Key factors propelling this growth include the rising global incidence of chronic headache disorders and a distinct clinical transition from acute symptom management toward preventive care strategies. Furthermore, the preference for therapies offering better safety profiles than traditional triptans is bolstering the adoption of these targeted treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.62 Billion
Market Size 2031USD 6.32 Billion
CAGR 2026-20319.73%
Fastest Growing SegmentOral
Largest MarketNorth America

Conversely, market growth faces substantial hurdles due to the stigmatization and trivialization of migraine conditions, which often result in postponed diagnoses and limited access to cutting-edge treatments. This lack of validation restricts the eligible patient base for prescription therapies, as highlighted by the European Migraine & Headache Alliance in 2024, which noted that 74% of migraine patients felt their condition was not taken seriously by medical professionals. Consequently, these barriers to professional acknowledgement significantly hinder the widespread adoption and reimbursement of premium CGRP inhibitor therapies.

Market Driver

The rising global prevalence of migraine and headache disorders serves as the primary engine for market expansion, generating urgent demand for targeted therapeutics with efficacy superior to non-specific treatments. The substantial burden of this disease, marked by debilitating pain and economic consequences, has prompted a shift toward mechanism-specific interventions like CGRP inhibitors that satisfy high unmet medical needs. Environmental factors are aggravating this trend; as reported by National Geographic in December 2025 regarding the 'mysterious rise of migraines,' research from the American Headache Society's annual meeting indicated a 6% rise in headache occurrence for every 10-degree Fahrenheit increase in outdoor temperature. This increasing frequency enlarges the potential patient population, necessitating strong preventive strategies, a scale underscored by the World Health Organization's October 2025 fact sheet stating that headache disorders impact roughly 40% of the global population.

Furthermore, innovations in drug delivery systems, especially the creation of oral small molecule antagonists known as gepants, have hastened market growth by providing non-invasive alternatives to injectable monoclonal antibodies. The ease of oral administration improves patient adherence and expands prescribing opportunities to cover episodic migraine cases that were historically treated with less effective acute medications. This technological evolution is fueling significant sector revenue; for instance, AbbVie reported in its 'Full-Year and Fourth-Quarter 2024 Financial Results' in January 2025 that combined global net revenues for its oral CGRP portfolio, comprising Ubrelvy and Qulipta, hit $1.664 billion. Such rapid commercial adoption illustrates the market's clear preference for convenient administration methods, validating the pharmaceutical industry's strategic expansion into delivery mechanisms beyond traditional injectables.

Market Challenge

The stigmatization and trivialization of migraine disorders present a significant obstacle to the growth of the Global CGRP Inhibitor Market. This pervasive invalidation frequently deters patients from pursuing specialized medical advice, leading them to depend on ineffective acute treatments instead of seeking preventive measures. When the condition is minimized as merely a headache, patients are unlikely to consult neurologists, who serve as the primary prescribers of advanced CGRP inhibitors. This separation effectively creates a bottleneck in the patient pipeline, precluding a substantial segment of the eligible population from obtaining accurate diagnoses and accessing advanced pharmacotherapies.

Additionally, societal skepticism adversely impacts healthcare utilization and reimbursement structures, thereby restricting the commercial uptake of premium treatments. Data from the American Migraine Foundation in 2024 revealed that 31.7% of individuals with active migraine frequently experienced stigma, a factor correlated with higher disability burdens. This widespread lack of acknowledgement reduces the urgency for payers to authorize coverage for these expensive biologics. As a result, the market encounters difficulties in translating high disease prevalence into tangible revenue growth, as the social dismissal of the condition limits the adoption of these targeted interventions.

Market Trends

The convergence of acute and preventive prescribing is fundamentally reshaping the market, transitioning away from the historical model of separated treatment regimens. This trend is characterized by the widespread adoption of dual-action therapies that enable patients to manage active migraine attacks and prevent future occurrences with a single pharmacological agent, thereby lowering pill burden and enhancing compliance. This flexibility fills a crucial gap for patients with variable headache frequencies who previously managed complex polypharmacy regimens. The commercial success of this shift is demonstrated by the performance of flexible oral agents; as noted in Pfizer's 'Third-Quarter 2024 Financial Results' from October 2024, global operational revenue for its dual-indicated CGRP inhibitor, Nurtec ODT/Vydura, rose by 45% year-over-year, confirming the clinical preference for streamlined interventions that provide mechanism-specific control.

Concurrently, the increasing use of combination therapies is gaining momentum as a method to treat refractory cases that do not respond to monotherapy. While oral small molecules focus on convenience, there is a distinct and expanding patient sub-segment requiring high-efficacy intravenous formulations, frequently administered in conjunction with other modalities like onabotulinumtoxinA to achieve symptom suppression. This intensification strategy generates significant value within the infusion category, distinguishing it from the mass-market oral sector. The demand for potent, provider-administered options is supported by strong sales figures; according to Lundbeck's 'Interim Report for the First Nine Months of 2024' released in November 2024, revenue for its intravenous CGRP inhibitor, Vyepti, increased by 76% over the prior year, highlighting the market's growing reliance on advanced delivery formats for the most severe and resistant patient profiles.

Key Market Players

  • Eli Lilly and Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • AbbVie Inc.
  • Amgen Inc
  • Novartis AG
  • Allergan
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Sun Pharmaceutical Industries Ltd

Report Scope

In this report, the Global CGRP Inhibitor Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CGRP Inhibitor Market, By Treatment

  • Preventive
  • Acute

CGRP Inhibitor Market, By Route of Administration

  • Oral
  • Nasal
  • Intravenous

CGRP Inhibitor Market, By End-User

  • Hospitals
  • Pharmacies
  • Specialty Clinics

CGRP Inhibitor Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CGRP Inhibitor Market.

Available Customizations:

Global CGRP Inhibitor Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CGRP Inhibitor Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Preventive, Acute)
    • 5.2.2. By Route of Administration (Oral, Nasal, Intravenous)
    • 5.2.3. By End-User (Hospitals, Pharmacies, Specialty Clinics)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America CGRP Inhibitor Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Route of Administration
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States CGRP Inhibitor Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada CGRP Inhibitor Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico CGRP Inhibitor Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By End-User

7. Europe CGRP Inhibitor Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Route of Administration
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany CGRP Inhibitor Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By End-User
    • 7.3.2. France CGRP Inhibitor Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom CGRP Inhibitor Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy CGRP Inhibitor Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain CGRP Inhibitor Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By End-User

8. Asia Pacific CGRP Inhibitor Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Route of Administration
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China CGRP Inhibitor Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By End-User
    • 8.3.2. India CGRP Inhibitor Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan CGRP Inhibitor Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea CGRP Inhibitor Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia CGRP Inhibitor Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By End-User

9. Middle East & Africa CGRP Inhibitor Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Route of Administration
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia CGRP Inhibitor Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE CGRP Inhibitor Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa CGRP Inhibitor Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By End-User

10. South America CGRP Inhibitor Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Route of Administration
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil CGRP Inhibitor Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia CGRP Inhibitor Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina CGRP Inhibitor Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global CGRP Inhibitor Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eli Lilly and Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Teva Pharmaceutical Industries Ltd
  • 15.4. AbbVie Inc.
  • 15.5. Amgen Inc
  • 15.6. Novartis AG
  • 15.7. Allergan
  • 15.8. Biohaven Pharmaceutical Holding Company Ltd.
  • 15.9. Sun Pharmaceutical Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer